[October 26, 2017]

Congenital Heart Disease - Global Clinical Trials Landscape 2017 - Research and Markets

The "Congenital Heart Disease Global Clinical Trials Review, H1, 2017" clinical trials has been added to Research and Markets' offering.

The clinical trial report provides an overview of Congenital Heart Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Congenital Heart Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe.

The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). It enhances the decision making capabilities and helps to create an effective counter stategies to gain competitive advantage.

Scope of the Report:

• The report provides a snapshot of the global clinical trials landscape
• Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
• The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
• The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
• The Report provides enrollment trends for the past five years
• Report provides latest news for the past three months

Companies Mentioned:

• Johnson & Johnson
• Bristol-Myers Squibb Company
• Asklepion Pharmaceuticals LLC
• The Lundbeck Foundation
• Sanofi
• Pfizer Inc
• AstraZeneca Plc
• Argint International Kft
• Advocate Health Care
• AbbVie Inc

For more information about this clinical trials report visit https://www.researchandmarkets.com/research/22wx5j/congenital_heart

View source version on businesswire.com: http://www.businesswire.com/news/home/20171026005761/en/

[ Back To TMCnet.com's Homepage ]